Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bardoxolone methyl - Reata Pharmaceuticals

Drug Profile

Bardoxolone methyl - Reata Pharmaceuticals

Alternative Names: Bard - Reata Pharmaceuticals; CDDO-Me; NSC-713200; RTA-402

Latest Information Update: 14 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dartmouth College; University of Texas M. D. Anderson Cancer Center
  • Developer Kyowa Kirin; Reata Pharmaceuticals; University of Texas M. D. Anderson Cancer Center
  • Class Anti-inflammatories; Antihypertensives; Antineoplastics; Antivirals; Hepatoprotectants; Obesity therapies; Small molecules; Triterpenes; Urologics
  • Mechanism of Action Cyclo-oxygenase 2 inhibitors; I-kappa B kinase inhibitors; NF E2 related factor 2 stimulants; NF-kappa B inhibitors; Nitric oxide synthase type II inhibitors; STAT3 transcription factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary arterial hypertension; Hereditary nephritis; Pancreatic cancer; Autosomal dominant polycystic kidney disease
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Autosomal dominant polycystic kidney disease; Diabetic nephropathies; Hereditary nephritis; Pulmonary arterial hypertension; Pulmonary hypertension; Renal failure
  • Phase I Obesity
  • Discontinued Haematological malignancies; Malignant melanoma; Non-alcoholic steatohepatitis; Pancreatic cancer; Solid tumours; Viral hepatitis

Most Recent Events

  • 11 Nov 2019 Reata Pharmaceuticals announces intention to submit an NDA and other regulatory application for marketing approval to the US FDA and globally for Hereditary nephritis
  • 11 Nov 2019 Updated efficacy, adverse events and pharmacodynamics data from the phase II/III CARDINAL trial in Hereditary nephritis released by Reata Pharmaceuticals
  • 10 Oct 2019 Reata Pharmaceuticals reacquires rights from AbbVie to develop and commercialise bardoxolone methyl worldwide outside of the USA, China, Japan, South Korea, South-East Asia and Taiwan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top